PharmacyCodes



Omapatrilat [Usan] en es it fr

Omapatrilat [Usan] Brand names, Omapatrilat [Usan] Analogs

Omapatrilat [Usan] Brand Names Mixture

  • No information avaliable

Omapatrilat [Usan] Chemical_Formula

C19H24N2O4S2

Omapatrilat [Usan] RX_link

No information avaliable

Omapatrilat [Usan] fda sheet

Omapatrilat [Usan] msds (material safety sheet)

Omapatrilat [Usan] Synthesis Reference

No information avaliable

Omapatrilat [Usan] Molecular Weight

408.537 g/mol

Omapatrilat [Usan] Melting Point

No information avaliable

Omapatrilat [Usan] H2O Solubility

No information avaliable

Omapatrilat [Usan] State

Solid

Omapatrilat [Usan] LogP

2.541

Omapatrilat [Usan] Dosage Forms

No information avaliable

Omapatrilat [Usan] Indication

For the treatment of hypertension

Omapatrilat [Usan] Pharmacology

Omapatrilat is used to treat hypertension. Vasopeptidase inhibitor that simultaneously inhibits angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). Omapatrilat lowers blood pressure by inhibiting the action of the angiotensin converting enzyme (ACE), which causes blood vessels to constrict. But unlike other drugs, omapatrilat also inhibits another enzyme known as neutral endopeptidase (NEP), which helps blood vessels relax. Omapatrilat demonstrated greater reduction in blood pressure than the ACE inhibitor lisinopril in individuals with salt-sensitive hypertension who typically do not respond well to ACE inhibitors.

Omapatrilat [Usan] Absorption

The absolute oral bioavailability of omapatrilat is 20% to 30% and the absorption is not affected by food intake.

Omapatrilat [Usan] side effects and Toxicity

Side effects include hyperkalemia, cough, hypotension, increased SrCr, and dizziness. Dizziness, diarrhea, vision disturbance, hypotension and angioedema

Omapatrilat [Usan] Patient Information

No information avaliable

Omapatrilat [Usan] Organisms Affected

Humans and other mammals